Drug Trial Radar · NCT07418736
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Jul 1, 2027
Study completion Oct 10, 2027
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe Chronic Obstructive Pulmonary Disease. The study consists of a screening period of up to 4 weeks, a randomized treatment period of 24 to 52 weeks, and a 12-week safety follow-up period.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
CM326 dose 1Drug
subcutaneous injection
CM326 dose 2Drug
subcutaneous injection
PlaceboOther
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Acute ExacerbationsTime frame: week 24-52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.